A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Belantamab mafodotin (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms DREAMM 2
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
Most Recent Events
- 23 Oct 2024 Status changed from active, no longer recruiting to completed.
- 27 Aug 2024 Planned End Date changed from 1 Jul 2024 to 30 Aug 2024.
- 16 Dec 2023 Planned End Date changed from 31 Aug 2023 to 1 Jul 2024.